A5197: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。主要假设：中断抗逆转录病毒治疗后第12周和第16周，在中断抗逆转录病毒治疗前接受MRK Ad5疫苗的受试者的几何平均HIV-1 RNA水平将低于接受安慰剂的受试者。在中断抗逆转录病毒治疗后16周，在中断抗逆转录病毒治疗前接受MRK Ad5疫苗的受试者的Log10 HIV-1 RNA拷贝数/mL与日功能的曲线下的时间平均面积将低于接受安慰剂的受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Hypothesis: The week 12 and week 16 post-ART interruption geometric mean HIV-1 RNA levels will be lower among subjects who had received MRK Ad5 vaccine prior to ART interruption than among subjects who received placebo. The time average area under the curve of the Log10 HIV-1 RNA copies/mL versus day function in the 16 week post-ART interruption step will be lower among subjects who receive the MRK Ad5 vaccine prior to ART interruption than among subjects who receive placebo.